Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfotep is an organophosphate insecticide and acaricide primarily used as a fumigant in greenhouses. It is a highly toxic small molecule that acts as an irreversible inhibitor of acetylcholinesterase, leading to the accumulation of acetylcholine at nerve synapses and disruption of normal nervous system function in insects and mammals. Sulfotep was first commercially launched by Bayer in 1946. It is absorbed via oral, dermal, or inhalational routes and metabolized through desulfuration followed by hydrolysis; excretion occurs mainly via urine. Due to its high toxicity, it poses significant risks to human health upon exposure[1][2][3][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfotep.